Activation and targetability of TYMP–IL-6–TF signaling in the skin microenvironment in uremic calciphylaxis
- 23 April 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (795) , eadn5772
Abstract
Calciphylaxis is an orphan disease characterized by dermal microvessel thrombosis, inflicting painful cutaneous necrosis. It occurs predominantly in patients with end-stage kidney disease and has high mortality, elusive pathogenesis, and no approved therapies. We demonstrate that sera from patients with calciphylaxis induced de novo synthesis of interleukin-6 (IL-6) and soluble IL-6 receptor (IL-6R) and stimulated Janus kinase-2 (JAK) and signal transducer and activator of transcription (STAT)–3 phosphorylation in primary human dermal microvascular endothelial cells (ECs). Calciphylaxis skin demonstrated an altered microenvironment characterized by a gain of proximal and distal IL-6 ligand-receptor interactions. Microvessels are the predominant senders and recipients of IL-6 signaling, which, along with up-regulated A disintegrin and metalloproteinase 17 in dermal vasculature and interstitial IL-6R, supported trans–IL-6 signaling in calciphylaxis lesions. Calciphylaxis serum up-regulated thymidine phosphorylase (TYMP) in ECs. TYMP up-regulated IL-6, which activated tissue factor (TF), a primary trigger of the extrinsic coagulation cascade. IL-6–TF signaling in ECs was partially triggered by elevated IL-6 and kynurenine amounts in calciphylaxis serum and was inhibited by anti–IL-6 treatment. The TF-inducing ability of calciphylaxis serum is correlated with disease activity and response to IL-6 inhibitors in ECs. Calciphylaxis is therefore a combination of serum-inducing TYMP–IL-6–TF signaling in ECs and a heterogeneous permissive local dermal microenvironment. The latter is characterized by microvessels initiating IL-6 signaling and multiway cross-talk with adipocytes and eccrine glands, perpetuating the sinister thrombotic milieu. Our results support exploring the IL-6–TF–inducing ability of calciphylaxis serum as an activity marker and IL-6 as a therapeutic target for uremic calciphylaxis.Keywords
This publication has 43 references indexed in Scilit:
- Intravenous Sodium Thiosulphate for Calciphylaxis of Chronic Kidney DiseaseJAMA Network Open, 2023
- Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative ColitisJAMA, 2023
- Clinical mimickers of calciphylaxis: A retrospective studyJournal of the American Academy of Dermatology, 2021
- A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signalingiScience, 2021
- Assessment of outcomes of calciphylaxis lesions treated with intralesional sodium thiosulfateJournal of the American Academy of Dermatology, 2021
- Management of Cutaneous CalciphylaxisAdvances in Therapy, 2020
- IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2Bone, 2019
- An Update on CalciphylaxisAmerican Journal of Clinical Dermatology, 2018
- Calciphylaxis: Natural history, risk factor analysis, and outcomeJournal of the American Academy of Dermatology, 2007
- The soluble interleukin‐6 receptor is generated by sheddingEuropean Journal of Immunology, 1993